Selective Potentiation of the Hypoxic Cytotoxicity of Tirapazamine by its 1-N-Oxide Metabolite SR 4317

Cancer Research

Volumn 64, Issue 2, 2004, Pages 736-742

  Siim, Bronwyn G ^a,b   Pruijn, Frederik B ^a   Sturman, Joanna R ^a   Hogg, Alison ^a   Hay, Michael P ^a   Brown, J Martin ^c   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 1,2,4 BENZOTRIAZINE 1 OXIDE; METRONIDAZOLE; MISONIDAZOLE; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

ARTICLE; CANCER CHEMOTHERAPY; CELL KILLING; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DIFFUSION COEFFICIENT; DNA STRAND BREAKAGE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; OXIDATION; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; PHARYNGEAL NEOPLASMS; TRIAZINES; UTERINE CERVICAL NEOPLASMS;

EID: 1642475109     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2488     Document Type: Article

References (32)

1. Brown, J. M. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res., 59: 5863-5870, 1999.
2. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth. Nature Rev. Cancer (Phila.), 2: 38-47, 2002.
3. von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson. L. O., Clark, P., Talbot, D., Rey, A., Butler, T. W., Hirsh, V., Olver, I., Bergman, B., Ayouh, J., Richardson, G., Dunlop, D., Arcenas, A., Vescio, R., Viallet, J., and Treat, J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J. Clin. Oncol., 18: 1351-1359, 2000.
4. Rischin, D., Peters, L., Smith, J., Macann, A., Denham, J., Poulsen, M., Jackson, M., Kenny, L., Penniment, M., and Fisher, R. Preliminary results of TROG 98.02 - a randomized phase II study of 5-fluorouracil, cisplatin and radiation versus tirapazamine, cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol., 22(Suppl.): 495-499, 2003.
5. Durand, R. E., and Olive, P. L. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat. Oncol. Investig., 5: 213-219, 1997.
6. Durand, R. E., and Olive, P. L. Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol. Biol. Phys., 22: 689-692, 1992.
7. Hicks, K. O., Fleming, Y., Siim, B. G., Koch, C. J., and Wilson, W. R. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys., 42: 641-649, 1998.
8. Kyle, A. H., and Minchinton, A. I. Measurement of delivery and metabolism of tirapazamine to tumor tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol., 43: 213-220, 1999.
9. Hicks, K. O., Pruijn, F. B., Sturman, J. R., Denny, W. A., and Wilson, W. R. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layers. Cancer Res., 63: 5970-5977, 2003.
10. Daniels, J. S., and Gates, K. S. DNA Cleavage by the Antitumor agent 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. J. Am. Chem. Sec., 118: 3380-3385, 1996.
11. Kotandeniya, D., Ganley, B., and Gates, K. Oxidative DNA base damage by the antitumor agent 3-amino-1, 2, 4-benzotriazine 1, 4-Dioxide (Tirapazamine). Bioorg. Med. Chem. Lett., 12: 2325, 2002.
12. Zagorevskii, D., Song, M., Breneman, C., Yuan, Y., Fuchs, T., Gates, K. S., and Greenlief, C. M. A mass spectrometry study of tirapazamine and its metabolites: Insights into the mechanism of metabolic transformations and the characterization of reaction intermediates. J. Am. Soc. Mass Spectrom., 14: 881-892, 2003.
13. Anderson, R. F., Shinde, S. S., Hay, M. P., Gamage, S. A., and Denny, W. A. Activation of 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc., 125: 748-756, 2003.
14. Biedermann, K. A., Wang, J., Graham, R. P., and Brown, J. M. SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br. J. Cancer, 63: 358-362, 1991.
15. Wang, J., Biedermann, K. A., and Brown, J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res., 52: 4473-4477, 1992.
16. Delahoussaye, Y. M., Evans, J. W., and Brown, J. M. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem. Pharmacol., 62: 1201-1209, 2001.
17. Jons, G. D., and Weinfeld, M. Dual action of tirapazamine in the induction of DNA strand breaks. Cancer Res., 56: 1584-1590, 1996.
18. Daniels, J. S., Gates, K. S., Tronche, C., and Greenberg, M. M. Direct evidence for bimodal DNA damage induced by tirapazamine. Chem. Res. Toxicol., 11: 1254-1257, 1998.
19. Hwang, J. T., Greenberg, M. M., Fuchs, T., and Gates, K. S. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1′-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions. Biochemistry, 38: 14248-14255, 1999.
20. Ban, F., Gauld, J. W., and Boyd, R. J. Modeling the action of an antitumor drug: a density functional theory study of the mechanism of tirapazamine. J. Am. Chem. Soc., 123: 7320-7325, 2001.
21. Hay, M. P., Gamage, S. A., Kovacs, M. S., Pruijn, F. B., Anderson, R. F., Patterson, A. V., WiIson, W. R., Brown, J. M., and Denny, W. A. Structure-activity relationships of 1, 2, 4-benzotriazine 1, 4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem., 46: 169-182, 2003.
22. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anti-cancer-drug screening. J. Natl. Cancer Inst., 82: 1107-1112, 1990.
23. Hicks, K. O., Ohms, S. J., van Zijl, P. L., Denny, W. A., Hunter, P. J., and Wilson, W. R. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br. J. Cancer, 76: 894-903, 1997.
24. Wilson, W. R., Pullen, S. M., Hogg, A., Hobbs, S. M., Pruijn, F. B., and Hicks, K. O. In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors. In: C. J. Springer (ed.), Suicide Gene Therapy: Methods and Reviews, pp. 403-432. Totowa: Humana Press, 2003.
25. Hicks, K. O., Pruijn, F. B., Baguley, B. C., and Wilson, W. R. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. J. Pharmacol. Exp. Ther., 297: 1088-1098, 2001.
26. Lee, A. E., and Wilson, W. R. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol. Appl. Pharmacol., 163: 50-59, 2000.
27. Wardman, P. The mechanism of radiosensitization by electron-affinic compounds. Radiat. Phys. Chem., 30: 423-432, 1987.
28. Denekamp, J., and Fowler, J. F. Radiosensitization of solid tumors by nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys., 4: 143-151, 1978.
29. Walton, M. I., and Workman, P. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233: NSC 130181) in mice. J. Pharmacol. Exp. Ther., 265: 938-947, 1993.
30. Overgaard, J., and Horsman, M. R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin. Radiat. Oncol., 6: 10-21, 1996.
31. Ward, J. F. Biochemistry of DNA lesions. Radiat. Res., 104: S103-S111, 1985.
32. Peters, K. B., and Brown, J. M. Tirapazamine: A hypoxia-activated topoisomerase 11 poison. Cancer Res., 62: 5248-5253, 2002.